BEFORE THE NEW HAMPSHIRE BOARD OF PHARMACY CONCORD NH 03301

in the Multer of Multon Stelling Phagmodit Lie. #R2536 Docket No. 2022-PHARM-002

SETTLEMENT AGREEMENT

In order to avoid the delay and expense of further proceedings and to promote the best interests of the public and the practice of pharmacy, the New Hampshire Board of Pharmacy ("Board") and Meliasa Siciliano ("Respondent"), a pharmacist currently licensed in the State of New Hampshire, agree to resolve certain allegations of professional misconduct now pending before the Board in accordance with the following terms and conditions:

- 1. Pursuant to RSA 318:30, RSA 318:31, RSA 310-A:1-j, RSA310-A:1-l, and RSA 541-A:31, V, the Board has jurisdiction and authority to investigate and commence a disciplinary proceeding pertaining to allegations of professional misconduct committed by licensees. Pursuant to RSA 318:31, IV, RSA 310-A:1-k, III and RSA 541-A, V, the Board may at any time before or during a disciplinary proceeding resolve allegations of professional misconduct by a written Settlement Agreement approved by the board and licensees provided the complainant has an opportunity to comment upon the terms of the Settlement Agreement before the Settlement Agreement has been executed.
- On 01/01/2015, the Board first granted Respondent Pharmacist Lie. #R2536. The Respondent's has an expiration date of 12/31/2022.
- 3. On 02/02/2022, the Board received information concerning the reported loss of Fentanyl at Cheshire Medical Center where Respondent worked as a Pharmacist-in-Charge ("PIC")

M3

and issued an order suspending the Respondent's license on an emergency basis. On 04/22/2022 after hearing, the Board issued an order lifting the emergency suspension of the Respondent's license. On 05/27/2022, the Board issued a Notice of Adjudicative Hearing.

- 4. In response to the information received, the Board commenced an investigation on their own motion and obtained information from various sources including the Respondent pertaining to whether the Respondent's conduct constitutes misconduct pursuant to the Board's statutes and rules.
- 5. Respondent stipulates that if a disciplinary proceeding were to take place, Hearing Counsel could prove that Respondent violated Ph 704.11(b)(1), and Ph 704.11(b)(10) according to the following facts:
 - a. Respondent is a licensee of the Board.
 - b. Respondent has no history of prior disciplinary actions.
 - c. Respondent failed to control all drugs issued or dispensed in the pharmacy where she practiced between the dates of approximately September 2021 and January 2022.
 - d. Respondent failed to adequately supervise personnel in the prescription department between the dates of approximately September 2021 and January 2022.
 - e. Between the dates of approximately September 2021 and January 2022, the hospital where she was PIC experienced an unprecedented surge in COVID patients, transitioned from an automated dispensing machine platform of Pyxis to Omnicell, and operated without a third-party ADM software program for anomalous usage reporting.
 - f. On February 1, 2022, an ICU nurse reported a concern about a discrepancy caused by Nurse Alexandra Towle.

- g. Between August 1, 2021 and February 1, 2022, Nurse Towle diverted from Cheshire Medical Center 15,150 mL of Fentanyl 50 mCg/mL inj 50 mL bags; 100 mg of Midazolam 1 mg/mL inj 100 mL bags; 4 mg of Midazolam 1 mg/mL inj 2mL vials; 4 mg of Morphine 4 mg/mL 1 mL cartridge; 250 mCg of Fentanyl 50 mCg/mL inj 2 mL vials; 50 mg of Oxycodone 5 mg tab; and 0.5 mg of Lorazepam 2 mg/mL 1 mL vials.
- h. Between September 1, 2021 and February 1, 2022, Cheshire Medical Center nursing staff documentation failed to account for 16,100 mL of Fentanyl 50 mCg/mL 50 mL bags.
- i. During the relevant timeframe, the Respondent had assigned the duties to review controlled substance reports and resolve discrepancies to her Pharmacy Operations Manager, who thereafter failed to recognize months long patterns of loss and diversion occurring at Cheshire Medical Center, and consequently never alerted her to the above described diversion and deficient documentation.
- Respondent acknowledges that this conduct set forth in paragraph 5 constitutes grounds for the Board to impose disciplinary sanctions against Respondent pursuant to the RSA 318:29, II(g).
- 7. WHEREFORE, the Respondent consents to the Board imposing the following discipline pursuant to RSA 318:29 IV:
 - a. Respondent is REPRIMANDED for violating Board rules Ph 704.11(b)(1) and Ph 704.11(b)(10).
 - b. The Respondent shall pay a ADMINSTRATIVE FINE in the amount of One thousand dollars of which five hundred dollars (\$500.00) is suspended for a period



of three (3) years upon execution of this Settlement Agreement, provided no additional finding of professional misconduct is made by the Board based on a complaint filed during the three-year period. Five hundred (\$500.00) is due and payable within thirty (30) days from the effective date of this Settlement Agreement and according to the terms in paragraph 7.c.

c. All payments shall be in the form of a check or money order made payable to the Treasurer, State of New Hampshire. Each payment shall specify on the memo line whether the payment is for "PHARM Administrative Fine." Each payment shall be mailed with a printed copy of this Settlement Agreement. All payments shall be sent to:

ATTN: OPLC Finance and Board of Pharmacy
Office of Professional Licensure and Certification
7 Eagle Sq.
Concord, NH 03301

d. Respondent is required to meaningfully participate in a total of sixteen (16) hours of Board-approved CONTINUING EDUCATION courses in the topics of controlled substance security, storage, and documentation, substance abuse disorders, or other related topics. These hours shall be in addition to the hours required for renewal of licensure and shall be completed within one year from the effective date of this Settlement Agreement. Within fifteen (15) days of completing these required courses, Respondent shall notify Board and provide proof of completion of the course hours to the Board and provide a LETTER OF REFLECTION. The Letter of Reflection shall be in the Respondent's own words and shall demonstrate that the Respondent has achieved a satisfactory degree of

skill and understanding in the areas of deficiency as described in the above stated facts.

- of three (3) years from the effective date of this Settlement Agreement. If the Respondent subsequently seeks to practice as a PIC, she shall comply with all Board rules and requirements for application and demonstrate the necessary competency and capability to be a PIC.
- 8. The Respondent shall cooperate with the investigation and prosecution of any matters relating to controlled drug loss or diversion at Cheshire Medical Center.
- 9. The Board may consider Respondent's compliance with the terms and conditions herein in any subsequent proceeding before the Board regarding Respondent's license. Respondent's breach of any terms or conditions of this Settlement Agreement shall constitute unprofessional conduct and shall serve as a separate and sufficient basis for further disciplinary action by the Board.
- 10. Except as provided herein, this Settlement Agreement shall but the commencement of further disciplinary action by the Board based upon the misconduct described above. However, the Board may consider this misconduct as evidence of a pattern of conduct in the event that similar misconduct is proven against Respondent in the future.
- 11. This Settlement Agreement shall become a permanent part of the Respondent's file, which is maintained by the Board as a public document.
- 12. Respondent voluntarily enters into and signs this Settlement Agreement and states that no promises or representations have been made to Respondent other than those terms and conditions expressly stated herein.

- 13. The Board agrees that in return for Respondent's executing this Settlement Agreement, the Band will not proceed with the formul adjudiculory process based upon the facts described herein.
- 14. Respondent understands that Respondent's aution in entering into this Settlement Agreement is a final not and not subject to reconsideration or judicial review or appeal.
- 15. Respondent has had the opportunity to seek and obtain the advice of an attorney of Respondent's choosing in connection with his decision to enter into this Settlement Agreement.
- 16. Respondent understands that the Board must review and accept the terms of this Settlement Agreement. If the Board rejects any portion, the entire Settlement Agreement shall be null and void. Respondent specifically waives any claims that any disclosures made to the Board during its review of this Settlement Agreement has prejudiced Respondent's right to a fair and impartial hearing in the future If this Settlement Agreement is not accepted by the Board.
- 17. Respondent is not under the influence of any drugs or alcohol and is otherwise of sound mind at the time the Respondent signs this agreement.
- Respondent certifies that Respondent has read this document titled Settlement Agreement.

 Respondent understands that Respondent has the right to a formal adjudicatory hearing concerning this matter and that at said hearing Respondent would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on Respondent's own behalf, to contest the allegations, to present oral argument, and to appeal to the courts. Further, Respondent fully understands the nature, quality, and dimensions of these rights. Respondent understands that by signing this Settlement Agreement,

Respondent waives these rights as they pertain to the misconduct described herein. This Settlement Agreement shall take effect as an Order of the Board on the date it is signed by an authorized representative of the Board.

SETTLEMENT AGREEMENT Docket No. 2022-PHARM-002 Page 8 of 8

FOR RESPONDENT

1. Melisma Siciliano, have reviewed the foregoing Settlement Agreement settling misconduct allegations pending against me and, of my own free will and without duress, and being knowledgeable about all of the consequences, admit to the validity thereof, and agree to all of the terms of this Settlement Agreement. Further, I, Melissa Siciliano, knowingly and freely waive the right to further notice, opportunity for hearing, substantial evidence, and findings and conclusions with regard to the allegations, which have been settled by the terms of this Settlement Agreement.

Dated: July 18 . 2022

Melissa Siciliano Respondent

FOR THE BOARD

Dated: July 20, 2022

Rathefort RPh

(Print Name)

Office of Professional Licensure and

Certification

Authorized Representative of the NH Board of Pharmacy